Quick Takeaways
- Capital Research Global Investors filed SCHEDULE 13G/A for BioMarin Pharmaceutical Inc. Common Stock (BMRN).
- Disclosed ownership: 4.8%.
- Date of event: 31 Mar 2025.
Capital Research Global Investors - 31 Mar 2025 SCHEDULE 13G/A Report for BioMarin Pharmaceutical Inc. Common Stock (BMRN)
- Filing Manager
- Capital Research Global Investors
- Reporting Manager
- Capital Research Global Investors
- Symbol
- BMRN
- Shares outstanding
- 190,638,646 shares
- Disclosed Ownership
- 9,150,655 shares
- Ownership
- 4.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 May 2025, 11:32:29 UTC
- Date of event
- 31 Mar 2025
- Previous filing
- 13 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Capital Research Global Investors disclosed 4.8% ownership in BioMarin Pharmaceutical Inc. Common Stock (BMRN) on 31 Mar 2025."
What Changed
- Previous schedule filing date: 13 Feb 2025.
- Current filing was accepted on 13 May 2025, 11:32.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Capital Research Global Investors | 4.8% | 9,150,655 | 9,150,652 | 0 | Jae Won Chung | Vice President and Senior Counsel II, Capital Research and Management Company |